Imaging of gastrointestinal stromal tumour (GIST)

Clinical Radiology

Volumn 59, Issue 6, 2004, Pages 487-498

  Lau, Shunhk ^a   Tam, K F ^a   Kam, C K ^a   Lui, C Y ^a   Siu, C W ^b   Lam, H S ^a   Mak, K L ^a  

^a KWONG WAH HOSPITAL   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Gastrointestinal stromal tumour (GIST); Gastrointestinal tract; Imatinib; Neoplasm; Protein c kit; Protooncogene

Indexed keywords

BARIUM; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ABDOMINAL RADIOGRAPHY; ANGIOGRAPHY; BARIUM MEAL; CANCER LOCALIZATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM TUMOR; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; EPITHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MESENCHYME; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; SPINDLE CELL;

EID: 2942577571     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2003.10.018     Document Type: Review

References (21)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
2. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
3. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-64.
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-6.
5. Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumours: radiologic features with pathologic correlation. RadioGraphics 2003;23:283-304.
6. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
7. DeMatteo RP. The GIST of targeted cancer therapy: a tumour (gastrointestinal stromal tumour), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 2002;9: 831-9.
8. DeMatteo RP, Maki RG, Antonescu C, et al. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumour. Curr Probl Surg 2003;40: 144-93.
9. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
10. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002;38(Suppl. 5):S39-S51.
11. Burkill GJC, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226:527-32.
12. Chen MYM, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002;179:1059-62.
13. Hasegawa S, Semelka RC, Noone TC, et al. Gastric stromal sarcomas: correlation of MR imaging and histopathologic findings in nine patients. Radiology 1998;208:591-5.
14. Wong CT, Lee YW, Ho LWC, et al. Gastrointestinal stromal tumours of the small bowel-computed tomographic appearance, angiographic features, and potential pitfalls in digital subtraction angiography. J Hong Kong Coll Radiol 2002;5: 197-201.
15. Mak HKF, Leung CMY, Chan CW, et al. Gastrointestinal stromal tumours-a retrospective study of the clinical, endoscopic, and computed tomographic features. J Hong Kong Coll Radiol 2002;5:82-7.
16. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl. 5): S60-S55.
17. Demetri GD, Mehren MV, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
18. Plaat BEC, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18: 3211-20.
19. Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumours: a review. Hum Pathol 2002;33:478-83.
20. Lehnert T. Gastrointestinal sarcoma (GIST)-a review of surgical management. Ann Chir Gynaecol 1998;87: 297-305.
21. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002;346:683-93.